{
  "id": 20588542,
  "title": "Merck ends the sorry saga of BTK inhibitor it got from ArQule",
  "url": "https://urgent.news/2026/11/18/merck-ends-the-sorry-saga-of-btk-inhibitor-it-got-from-arqule",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T11:43:38.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/merck-ends-the-sorry-saga-of-btk-inhibitor-it-got-from-arqule/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Merck has ended development of a BTK inhibitor that was the main reason it bought ArQule for $2.7 billion in 2019. Nemtabrutinib, aka MK-1026, was being investigated in a slew of trials in blood cancers ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}